In this cancer, retinoic acid, used as a therapeutic agent for over a decade, was shown to bind to the promoters of ROR1 and WNTA5 to regulate their transcription, reducing cell proliferation and promoting cell differentiation, as evidenced by the increased expression of synaptophysin (90). The gene discussed is ROR1; the disease is cancer.